BOSTON — A new protein that can serve as both a drug target and a diagnostic biomarker for breast cancer was presented here this week at the Biomarker Pipeline conference.

The new protein, called GP88, was developed by the 5-year-old Columbia, Md.-based company A&G Pharmaceutical.

“From the beginning it was my intention to identify a target that had both diagnostic and therapeutic potential,” Ginette Serrero, the president and chief scientific officer of the company, told ProteoMonitor. “That was not an accident.”

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Researchers report that deleting one gene from butterflies affects their wing coloration patterns, according to the Washington Post.

The Seattle Times writes that pharmacogenomics testing can help choose medications that may work best for people with depression.

In PNAS this week: genome sequencing of weevil symbionts, retinoid X receptor deletion in lung cancer metastasis, and more.

Sequencing could help combat foodborne illnesses, according to a blog post by Food and Drug Administration officials.

Sponsored by

This online, interactive seminar will answer researchers’ most pressing questions about how to gain outstanding research results from proteomic studies.